Thomas Habermann, MD


Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma Space

Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.

Charles Meakin, MD, MHA


Colorectal Cancer Awareness Month: Overcoming Barriers to Early Detection

Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.

Toufic Kachaamy, MD


Artificial Intelligence and Machine Learning in Cancer Detection

Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.

Efstathios Kastritis, MD


Daratumumab Regimen May Be the More Active Therapy Needed for Amyloidosis

Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.

Sponsored Content by The Janssen Pharmaceutical Companies of Johnson & Johnson


Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.

Hannah Burke


Company-wide Initiative Will Provide Standards for Collection and Storage

The Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.

Michael Tees, MD


Exploring The Donor-Derived CAR T-Cell Therapy, ALLO-501A

Michael T. Tees, MD, discusses chimeric antigen receptor T-cell therapies, including ALLO-501A, and its use for patients with relapsed or refractory large B-cell lymphoma.

Prerna Mewawalla, MD


Recent Trials Change Practice for Newly Diagnosed Multiple Myeloma

Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.

William H. Bradley, MD


Olaparib Trial Supports 2-Year Treatment Duration in Ovarian Cancer

William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.

Mehmet Akce, MD


Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma

Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.

Neeta Somaiah, MD


Expanding the Use of Targeted Therapies in GIST

Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.

Matthew L. Anderson MD, PhD


Niraparib Results Encourage Somatic Tumor Profiling in Ovarian Cancer

Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.

Yuliya Mikheeva, MD


Challenges Remain in Treating Anaplastic Thyroid Cancer

Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.

Christian Buske, MD


Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.

Karen Kelly, MD


Questioning When to Start Immunotherapy for Patients With Oncogenic Drivers

Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.

Mark J. Roschewski, MD


Copanlisib and Rituximab Show Efficacy in Follicular Lymphoma

Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.

Brea C. Lipe, MD


Lipe Discusses Therapeutic Options for a Patient With Transplant-Ineligible Multiple Myeloma

"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."

Adam S. DuVall, MD


Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?

Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.

Alan Bryce, MD


PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Hong Tang, MD, FACP


Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive Care

In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.

Masahiro Tsuboi, MD


Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.

Andrew Wei, MBBS, PhD


MRD Linked to Long-Term Survival With Azacitidine Therapy in AML

Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

Jeffrey S. Miller, MD


Future Directions for NK Cell Platforms in Hematologic Malignancies

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

Bruce Feinberg


Manipulating T Cells to Treat Patients With Cancer

Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.

Nelson J. Chao, MD


Closing Thoughts on the GVHD Treatment Landscape

Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.

Evanthia Roussos Torres, MD, PhD


What’s Next for the HER2-Negative Breast Cancer Space?

Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.

Adam Cohen, MD


Addressing Toxicities of BCMA-Targeted Therapy for Multiple Myeloma

Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.

Liza C. Villaruz, MD


Villaruz Discusses Updates in Biomarker-Driven Lung Cancer

Liza C. Villaruz, MD, discusses the latest areas of growth in the non–small cell lung cancer space.